PrIME Biologics

What PrIME Biologics does

PrIME Biologics Pte Limited is a Singapore-based private biologics company founded in 2010, operating with a workforce of 101-250 employees per firmographic records. The firmographic short description indicates the company "develops a disposable procedure," implying activity in single-use medical devices or biologics consumables, though no product names, indications, mechanism of action, or technical specifications are disclosed in the available sources.

The company's online presence is minimal: primebiologics.com presents only an "Innovative Biological Solutions" tagline, a contact form, and a 2025 copyright notice. There are no detailed product descriptions, technical disclosures, regulatory milestones, quality system certifications, patents, partnership announcements, customer references, or press content in any of the source blocks. No certifications and compliance, partnerships and alliances, or proprietary technology features are documented.

Commercially, the company has no publicly disclosed pricing, revenue model, distribution channels, or go-to-market motion. Capital history consists of a single funding round on 2014-10-08 of approximately $12.6M led by Xeraya Capital with co-investment from JP Asia Prime Capital and Pulau Manukan Ventures, an investor profile consistent with a life sciences / medtech positioning. Leadership comprises Hari Nair (Executive Chairman) and John Manusu (Managing Director & Director). No subsequent funding events, M&A activity, product launches, or material strategic actions are documented across roughly the past decade of available data, leaving the current commercial trajectory largely unobservable.

Name

PrIME Biologics

Legal name

Prime Biologics

Website

https://primebiologics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

PrIME Biologics is a Singapore-based private biologics company founded in 2010 that develops a disposable procedure product, operating with 101-250 employees and last funded in 2014.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

akta.pro secondary industries

Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

Keywords

• Biological solutions
• Biopharmaceutical products
• Disposable medical devices
• Life sciences products
• Biotech manufacturing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Core offering

Prime Biologics develops and supplies innovative biological solutions, including a disposable procedure product, targeted at the biopharmaceutical and life sciences industries. The company operates as a Singapore-based product developer with proprietary biological technology capabilities and a workforce of 101–250 employees supporting product development, manufacturing, and commercial delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• Disposable Procedure A disposable procedure product developed by PrIME Biologics Pte Limited, offered as part of the company's innovative biological solutions portfolio for enterprise biopharma and life sciences customers.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• Lonza Group: World's largest biologics CDMO offering mammalian and microbial biologics manufacturing, cell and gene therapy services, and integrated bioprocessing solutions. Directly comparable as a biologics manufacturing services and bioprocessing technology provider, though at vastly greater scale and breadth.
• Samsung Biologics: South Korea-based large-scale biologics CDMO operating some of the world's largest single-site mammalian cell culture facilities. Comparable as an Asia-based biologics manufacturing services provider, though at much larger scale and focused on high-volume commercial supply.
• Thermo Fisher Scientific (Patheon CDMO): Global life sciences leader offering biologics contract manufacturing services through its Patheon CDMO business, alongside bioprocessing technologies, single-use systems, and analytical tools. Comparable as both a biomanufacturing services peer and a supplier of bioprocessing technology.
• Sartorius AG: Leading bioprocess solutions provider specializing in single-use technologies, filtration, fermentation, and cell culture media used in biologics manufacturing. Comparable as a supplier of single-use/disposable bioprocessing technology that underpins biologic manufacturing workflows.
• Cytiva (Danaher): Global provider of bioprocessing technologies, single-use systems, and process development tools for the biologics industry. Comparable as a supplier of bioprocess development and single-use manufacturing technology used by biologics manufacturers.
• Recipharm (now part of CRODA): European-headquartered CDMO providing biologics and sterile fill-finish manufacturing services. Comparable as a contract biologics manufacturing services peer competing for outsourced manufacturing projects from biopharma companies.
• Baxter BioPharma Solutions: Global contract manufacturer of biologics and injectables, including plasma-derived therapies and other complex biologics. Comparable as a contract biologics manufacturer with particular strength in plasma-based and complex biologic products.

Direct peers

• WuXi Biologics: Hong Kong-listed end-to-end biologics CRDMO (Contract Research, Development and Manufacturing Organization) providing discovery, development, and manufacturing services for biologics globally, including a major Singapore presence. Comparable as an Asia-headquartered biologics manufacturing services competitor with overlapping target customers.
• AGC Biologics: Global CDMO providing biologics manufacturing services including mammalian cell culture, microbial fermentation, and gene therapy. Comparable as a contract biologics manufacturing services peer competing for the same biopharma outsourcing customers.

Emerging players

• Stelis Biopharma: Emerging India-based biologics CDMO offering mammalian cell-culture based biosimilars and biologics manufacturing services. Comparable as a smaller-scale, regionally-headquartered biologics manufacturing services peer targeting similar biopharma customers in emerging Asia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/primebiologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PrIME Biologics